Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05).
Although the adrenal glands are not common sites of metastasis from hepatocellular carcinoma (HCC), this metastasis can be met in patients with advanced HCC in some clinical settings. However, the effectiveness of radiotherapy against such metastases is unclear. Therefore, we performed the present m...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4811532?pdf=render |
| _version_ | 1818510946435334144 |
|---|---|
| author | Jinhong Jung Sang Min Yoon Hee Chul Park Taek-Keun Nam Jinsil Seong Eui Kyu Chie Tae Hyun Kim Mi-Sook Kim Chul Yong Kim Hong Seok Jang Jong Hoon Kim |
| author_facet | Jinhong Jung Sang Min Yoon Hee Chul Park Taek-Keun Nam Jinsil Seong Eui Kyu Chie Tae Hyun Kim Mi-Sook Kim Chul Yong Kim Hong Seok Jang Jong Hoon Kim |
| author_sort | Jinhong Jung |
| collection | DOAJ |
| description | Although the adrenal glands are not common sites of metastasis from hepatocellular carcinoma (HCC), this metastasis can be met in patients with advanced HCC in some clinical settings. However, the effectiveness of radiotherapy against such metastases is unclear. Therefore, we performed the present multi-institutional study to investigate tumor response, overall survival (OS), treatment-related toxicity, and prognostic factors after radiotherapy. We retrospectively reviewed 134 patients who completed a planned radiotherapy for their adrenal metastases. Complete response was noted in 6 (4.3%), partial response in 48 (34.0%), and stable disease in 78 patients (55.3%). The median OS was 12.8 months, and the 1-, 2-, and 5-year OS rates were 53.1%, 23.9%, and 9.3%, respectively. Grade 3 anorexia occurred in 2 patients, grade 3 diarrhea in 1, and grade 3 fatigue in 1. Multivariate analyses revealed that the following factors had significant effects on OS: controlled intrahepatic tumor; controlled extrahepatic metastasis; and Child-Pugh class A. Although patients with adrenal metastasis from HCC had poor OS, radiotherapy provided an objective response rate of 38.3% and disease stability of 93.6%, with minimal adverse events. Therefore, radiotherapy for these patients could represent a good treatment modality, especially for patients with controlled intrahepatic tumors, controlled extrahepatic metastasis, and good hepatic function. |
| first_indexed | 2024-12-10T23:26:55Z |
| format | Article |
| id | doaj.art-40be375750c54b02b350dccf6b19423d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T23:26:55Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-40be375750c54b02b350dccf6b19423d2022-12-22T01:29:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e015264210.1371/journal.pone.0152642Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05).Jinhong JungSang Min YoonHee Chul ParkTaek-Keun NamJinsil SeongEui Kyu ChieTae Hyun KimMi-Sook KimChul Yong KimHong Seok JangJong Hoon KimAlthough the adrenal glands are not common sites of metastasis from hepatocellular carcinoma (HCC), this metastasis can be met in patients with advanced HCC in some clinical settings. However, the effectiveness of radiotherapy against such metastases is unclear. Therefore, we performed the present multi-institutional study to investigate tumor response, overall survival (OS), treatment-related toxicity, and prognostic factors after radiotherapy. We retrospectively reviewed 134 patients who completed a planned radiotherapy for their adrenal metastases. Complete response was noted in 6 (4.3%), partial response in 48 (34.0%), and stable disease in 78 patients (55.3%). The median OS was 12.8 months, and the 1-, 2-, and 5-year OS rates were 53.1%, 23.9%, and 9.3%, respectively. Grade 3 anorexia occurred in 2 patients, grade 3 diarrhea in 1, and grade 3 fatigue in 1. Multivariate analyses revealed that the following factors had significant effects on OS: controlled intrahepatic tumor; controlled extrahepatic metastasis; and Child-Pugh class A. Although patients with adrenal metastasis from HCC had poor OS, radiotherapy provided an objective response rate of 38.3% and disease stability of 93.6%, with minimal adverse events. Therefore, radiotherapy for these patients could represent a good treatment modality, especially for patients with controlled intrahepatic tumors, controlled extrahepatic metastasis, and good hepatic function.http://europepmc.org/articles/PMC4811532?pdf=render |
| spellingShingle | Jinhong Jung Sang Min Yoon Hee Chul Park Taek-Keun Nam Jinsil Seong Eui Kyu Chie Tae Hyun Kim Mi-Sook Kim Chul Yong Kim Hong Seok Jang Jong Hoon Kim Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). PLoS ONE |
| title | Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). |
| title_full | Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). |
| title_fullStr | Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). |
| title_full_unstemmed | Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). |
| title_short | Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). |
| title_sort | radiotherapy for adrenal metastasis from hepatocellular carcinoma a multi institutional retrospective study krog 13 05 |
| url | http://europepmc.org/articles/PMC4811532?pdf=render |
| work_keys_str_mv | AT jinhongjung radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT sangminyoon radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT heechulpark radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT taekkeunnam radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT jinsilseong radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT euikyuchie radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT taehyunkim radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT misookkim radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT chulyongkim radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT hongseokjang radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 AT jonghoonkim radiotherapyforadrenalmetastasisfromhepatocellularcarcinomaamultiinstitutionalretrospectivestudykrog1305 |